Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Firas Hamdan, Erkko Ylösmäki, Jacopo Chiaro, Yvonne Giannoula, Maeve Long, Manlio Fusciello, Sara Feola, Beatriz Martins, Michaela Feodoroff, Gabriella Antignani, Salvatore Russo, Otto Kari, Moon Hee Lee, Petrus Järvinen, Harry Nisen, Anna Kreutzman, Jeanette Leusen, Satu Mustjoki, Thomas G McWilliams, Mikaela Grönholm, Vincenzo Cerullo

Journal title: Journal for ImmunoTherapy of Cancer

Journal number: 9/8

Journal publisher: BMJ journal

Published year: 2021

Published pages: e003000

DOI identifier: 10.1136/jitc-2021-003000

ISSN: 2051-1426